acetaminophen; naproxen sodium - Profile
What are the generic drug sources for acetaminophen; naproxen sodium and what is the scope of freedom to operate?
Acetaminophen; naproxen sodium
is the generic ingredient in one branded drug marketed by Kenvue Brands and is included in one NDA. Additional information is available in the individual branded drug profile pages.DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for acetaminophen; naproxen sodium
Generic Entry Date for acetaminophen; naproxen sodium*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for acetaminophen; naproxen sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kenvue Brands | TYLENOL WITH NAPROXEN | acetaminophen; naproxen sodium | TABLET;ORAL | 219962-001 | Jul 24, 2026 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
